Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

William D Tutrone

Showing results (1-10 of 19) with videos related to

Pageof 2
Sort By:
Cutis|January 30, 2003
Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefaceptJeffrey M Weinberg, William D Tutrone
Journal of Drugs in Dermatology : JDD|December 24, 2009
Dissolving collagen fillers: enzymatic degradation of some problematic filler circumstances may now include collagensWilliam D Tutrone, Joel L Cohen
Archives of Dermatology|February 18, 2009
A case of erythematous hand depressionsWilliam D Tutrone, George Niedt, Stacy Salob
Idrugs : the Investigational Drugs Journal|January 20, 2004
Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefaceptWilliam D Tutrone, Rita Saini, Jeffery M Weinberg
Drugs & Aging|August 17, 2002
Viral skin infections in the elderly: diagnosis and managementRashmi Bansal, William D Tutrone, Jeffrey M Weinberg
Journal of Drugs in Dermatology : JDD|July 11, 2003
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefaceptJeffrey M Weinberg, Ritu Saini, William D Tutrone
Cutis|December 6, 2003
The Köbner phenomenon and psoriatic arthritisRitu Saini, William D Tutrone, Bruce E Strober
Current Pharmaceutical Design|January 11, 2005
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimusRitu Saini, William D Tutrone, Jeffrey M Weinberg
Cutis|February 7, 2002
Cutaneous anthrax: a concise reviewWilliam D Tutrone, Noah S Scheinfeld, Jeffrey M Weinberg
Clinics in Dermatology|March 1, 2003
Macrolides in dermatologyNoah S Scheinfeld, William D Tutrone, Omar Torres, et al.
Pageof 2

Showing results (1-10 of 19) with videos related to

Sort By:
Pageof 2
Cutis|January 30, 2003
Biologic therapy for psoriasis: the T-cell-targeted therapies efalizumab and alefaceptJeffrey M Weinberg, William D Tutrone
Journal of Drugs in Dermatology : JDD|December 24, 2009
Dissolving collagen fillers: enzymatic degradation of some problematic filler circumstances may now include collagensWilliam D Tutrone, Joel L Cohen
Archives of Dermatology|February 18, 2009
A case of erythematous hand depressionsWilliam D Tutrone, George Niedt, Stacy Salob
Idrugs : the Investigational Drugs Journal|January 20, 2004
Biological therapy for psoriasis: an overview of infliximab, etanercept, efalizumab and alefaceptWilliam D Tutrone, Rita Saini, Jeffery M Weinberg
Drugs & Aging|August 17, 2002
Viral skin infections in the elderly: diagnosis and managementRashmi Bansal, William D Tutrone, Jeffrey M Weinberg
Journal of Drugs in Dermatology : JDD|July 11, 2003
Biologic therapy for psoriasis--the first wave: infliximab, etanercept, efalizumab, and alefaceptJeffrey M Weinberg, Ritu Saini, William D Tutrone
Cutis|December 6, 2003
The Köbner phenomenon and psoriatic arthritisRitu Saini, William D Tutrone, Bruce E Strober
Current Pharmaceutical Design|January 11, 2005
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimusRitu Saini, William D Tutrone, Jeffrey M Weinberg
Cutis|February 7, 2002
Cutaneous anthrax: a concise reviewWilliam D Tutrone, Noah S Scheinfeld, Jeffrey M Weinberg
Clinics in Dermatology|March 1, 2003
Macrolides in dermatologyNoah S Scheinfeld, William D Tutrone, Omar Torres, et al.
Pageof 2